# Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

> **NCT04329949** · PHASE3 · TERMINATED · sponsor: **Corcept Therapeutics** · enrollment: 43 (actual)

## Conditions studied

- Metastatic Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** Relacorilant, 100 mg and 25 mg
- **DRUG:** Nab-paclitaxel

## Key facts

- **NCT ID:** NCT04329949
- **Lead sponsor:** Corcept Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-06-30
- **Primary completion:** 2021-08-23
- **Final completion:** 2022-03-25
- **Target enrollment:** 43 (ACTUAL)
- **Why stopped:** The independent data monitoring committee found no safety issues, however the observed response rate did not meet the predefined threshold for continuing the study. The study was terminated by the Sponsor.
- **Last updated:** 2023-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04329949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04329949, "Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04329949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*